Category Archives: Non-U.S. Practice

A Hidden Danger Under The EPC – The “Extension Trap”

Posted on March 14, 2012 by Warren Woessner

Provided to us by Dr. Stefan Danner of DHS Patentanwalts GmbH, find below the current issue of the biotech IP newsletter dealing with recent EPO case law on Article 123(2)(3) EPC. Extension Trap

Posted in Non-U.S. Practice | Tagged Dr. Steffan Danner, EPC, Patent Law, Warren Woessner | Leave a comment

Biotech IP Newsletters

Posted on December 6, 2011 by Warren Woessner

Find below biotech IP newsletters recently provided by Dr. Stefan Danner. SPCs For Combination Products – Opinion Of The Advocate General EPO Ruling On The Patentability Of Medical Treatments By Therapy

Posted in Non-U.S. Practice | Tagged Dr. Stefan Danner, EPO, intellectual property, Patent Law, Warren Woessner | Leave a comment

One step ahead and one step backward for the EU patent

Posted on March 22, 2011 by Warren Woessner

The following is a contribution from Camilla Rendal Nielsen of Zacco Denmark A/S 1. The EU Competiveness Council have authorised “enhanced cooperation” in the area of unitary patent protection, and. 2. The EU court now states that the proposed Patents Court … Continue reading →

Posted in Non-U.S. Practice | Tagged camilla rendal nielsen, EPO, EU Treaty, European patent, intellectual property, ip, IP law tools, Patent Law, patents, Warren Woessner, zacco | Leave a comment

Canadian Ruling Supports “Antibody Exception”

Posted on March 10, 2011 by Warren Woessner

In my recent post on the Centocor v. Abbott decision, I noted that the Fed. Cir. had at least preserved the “antibody exception,” which I define as permitting broad claims to structurally uncharacterized antibodies (monoclonal and polyclonal) if the structure … Continue reading →